Genus PLC (GNS)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 2,240.00 |
|---|---|
| 52-week range | 1,943.00 – 3,220.00 |
| Return, 1 month / 3 months | +5.1% / +2.8% |
| Return, 1 year / 3 years | −12.7% / +4.6% |
| Trend | Below its 200-day average |
| RSI (14) | 52 |
| Volatility (1 year) | 35.5% |
| Worst drawdown (1 year) | -38.0% |
| Average daily value traded | 414.21M GBX |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genus PLC is an animal genetics company based in the United Kingdom. It supplies breeding stock and genetic material, including bovine semen and pig genetics, to farmers and livestock producers. Its customers are agricultural businesses that raise cattle and pigs for meat and dairy production, and it operates across several countries. The company focuses on improving the productivity and health of farm animals through selective breeding and related technologies.
On this site Genus PLC appears as a stock on the London Exchange (UK), code GNS, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genus PLC (GNS) trades on the London Exchange in UK. It last closed at GBX 2,240.00 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,257 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.7% and over the last three months it rose 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.8% | ||
| From 52-week high | -29.3% | ||
| Momentum | 38 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 2.8% | ||
| 6-month return | -12.6% | ||
| 12-month return, skipping the last month | -16.9% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.0% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 414.21M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −5.1% |
|---|---|
| 1 month | +5.1% |
| 3 months | +2.8% |
| 6 months | −12.6% |
| 1 year | −12.7% |
| 3 years | +4.6% |
| 5 years | −56.9% |
Signals
| 50-day / 200-day average | 2,225.16 / 2,430.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 78.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Nov 2026 | GBP 0.2400 |
| 5 Mar 2026 | GBP 0.1120 |
| 6 Nov 2025 | GBP 0.2170 |
| 6 Mar 2025 | GBP 0.1030 |
| 7 Nov 2024 | GBP 0.2170 |
| 29 Feb 2024 | GBP 0.1030 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.